Having the North American region as its most dominant market, the global neoantigen cancer vaccine market size is projected to reach USD 1.38 billion by 2030 at a CAGR of 76% from 2022 to 2030. Neoantigens that arise from cancer-specific mutations are an additional class of antigens that are desirable for therapeutic cancer vaccines. Vaccination against tumour-specific neoantigens reduces the possibility of inducing central and peripheral tolerance, as well as the risk of autoimmunity. Recent preclinical and early-phase clinical studies have demonstrated that cancer vaccines based on neoantigens have significant therapeutic potential.
Cancer vaccines employ weakened or killed viruses, bacteria, or other infection-causing agents to elicit an immune response in the body. These vaccines are intended to have a similar effect, in which the immune system will recognise, attack, and destroy cancer cells. They identify cancer cells as foreign and consequently prime the immune system to attack them. Vaccines against cancer are one way to utilise the immune system to combat cancer.
Get more information on this report Download Sample Report
The growth of the market for Neoantigen cancer vaccines is primarily attributable to rapid technological advancements and improvements in the healthcare industry's infrastructure. In addition to this, the increasing investments by governments and other healthcare providers are expected to create opportunities for the global neoantigen cancer vaccine market over the next few years.
Nowadays, sedentary lifestyles, unhealthy diets, and at times even some sorts of addiction are catering to a rise in numbers of cancer cases. This drives the market for cancer treatment and the Neoantigen Cancer Vaccines. With new research and development now, it can be assured that Cancer can be prevented as well as cured.
As each person’s health conditions are different, and each body’s responses to medicine are different, with the increasing awareness, the adoption of Personalized Medicine to Tailor Patient's Treatment on an Individual Level has increased. This boosts the market for neoantigen cancer vaccine.
Although the adoption of personalised medicines acts as a boon for the market, this is quite an expensive process. Moreover, the research & development in this process and its setup also require more considerable investments. This requirement of high capital is restricting the growth of the neoantigen cancer vaccine market.
The new research and development are creating a lot of things for the market like reducing treatment gaps, reducing turnaround time and cost etc. This may boost the growth of the market in the near future. Also, the partnership and collaboration between various healthcare stakeholders are creating room for further research and development, which is predicted to drive the market in future.
The global neoantigen cancer vaccine market is segmented on the basis of product, neoantigen type, administration route, cell, technology, delivery mechanism, application, region, and company. The market can be segmented by route of administration into intravenous, intramuscular, transdermal, and other segments. The intravenous segment is anticipated to dominate the market, while the intramuscular segment is projected to grow at the fastest rate during the forecast period. This growth can be attributed to rapid response and the fact that drug dosage can be easily controlled. In addition, intramuscular injections may be used instead of intravenous injections for drugs that cause vein irritation when administered intravenously. This is anticipated to result in substantial growth of the intramuscular route of the administration segment over the next several years.
The application segment is subdivided further into lung, melanoma, digestive, and brain cancers, among others. As the neoantigen-based immunotherapy of OSE Immunotherapeutic, which is in development for the Tedopi (OSE2101) neoantigen cancer vaccine, is expected to launch in 2022, lung cancer will dominate the market during the forecast period. Tedopi (OSE2101) is used to treat patients with HLA-A2+ Non-small cell lung cancer (NSCLC). Currently, the vaccine is in clinical development phase III.
Regional Growth Insights Request Sample Pages
Due to the rising prevalence and incidence of lung cancer, melanoma, gastrointestinal, pancreatic cancer, and other solid tumour indications, North America is anticipated to be the leading regional market for neoantigen cancer vaccines over the forecast period. Countries like the United States of America are enriched with good healthcare infrastructure, and they are also investing massive amounts in research and development making them the most dominant regions in the global neoantigen cancer vaccine market.